indicating this diastereomer to be a direct antagonist of
CERT.1d,3 The crystal structures of the CERT START
domain, in complex with (1R,3R)-HPAs of varying acyl
chain lengths outlining the more significant role of stereo-
chemistry of the inhibitors, have been published recently.4
its aryl-substituted analogues, and also the (1R,3S)-HPA-
12 together with some 1-alkyl-substituted analogues of the
same stereochemistry.
Our strategy is based on the use of an expedient
straightforward transformation of enantiomerically and
diastereomerically pure oxoamino acids easily accessible
via the CIAT process from available substrates (Scheme 1).11
The application of 1-phenylethylamine (PEA) as a chiral
mediator in such a transformation is especially favorable
since both (R)- and (S)-enantiomers of PEA are commer-
cially available, with both antipodes of the final compounds
attainable. The required (1R,3R)-anti-relationship of 3-ami-
no-1-phenylbutane-1,4-diols was accomplished using (R)-
PEA and another CIAT process in tandem with reversible
acid-catalyzed lactonization.11a
Scheme 1. Crystallization-Induced Asymmetric Transforma-
tions (CIAT) Approaches to the Starting Oxoamino Acid
Derivatives
Scheme 2. Expedient Approach to the cis-Butanolide 2a
The oxoamino acids and their derivatives are now
recognized as the crucial intermediates for the HPA synthe-
sis, although other approaches have been presented.5 The
first synthesis of HPA-12 was published in 2001 by the
Kobayashi group.6 The asymmetric Mannich protocol
was improved by the same authors in the following years.7
While the C-N bond was introduced with high selectivity,
the diastereoselectivity of C-OH bond formation was
modest. For the last step of the synthesis, anti-stereoselec-
tive reduction of γ-oxoamino acid derivatives, both K-Se-
lectride and LiBEt3H have been used to give the expected
aminodiol in 9/91 (syn/anti) selectivity. Interestingly, the
selectivity dropped to 40/60 with traces of moisture in the
reaction media.8 Other strategies for the anti-1,3-amino
alcohol moiety in the same or related aminodiols provide
low stereoselectivity as well.9 Elsewhere, the stereoselective
synthesis of the anti-1,3-amino alcohol moiety via the
improved oxazolidine route in the racemic aminobutane-
diols was published only recently.10 In this paper, we
introduce viable scalable synthesis of (1R,3R)-HPA-12,
Sincein our previouspaper we describedthe preparation
of the trans-lactone 20f,12 we are now investigating mod-
ified conditions to reach the required (2R,5R)-derivative
(2a, Scheme 2). We are pleased to notice that a simple
raising of the reaction temperature from 25 up to 80 °C
under otherwise unchanged conditions (8 M HCl, 4 h) is
sufficient to achieve the transformation of trans-lactone 20f
to the thermodynamically more stable cis-butanolide 2a in
84% yield. Finally, optimal conditions for the required cis-
lactone 2a were realized in two steps-a one-pot procedure
starting from oxoamino acid 1a using a nonstereoselective
reduction with sodium borohydride (dr 2/1) followed by
acid-catalyzed lactonization under the formerly described
conditions.11a Under these conditions, the lactonization
occurred smoothly and the desired product 2a started to
seed within 30 min of the reaction.
(3) Yasuda, S.; Kitagawa, H.; Ueno, M.; Ishitani, H.; Fukasawa, M.;
Nishijima, M.; Kobayashi, S.; Hanada, K. J. Biol. Chem. 2001, 276,
43994–44002.
(4) Kudo, N.; Kumagai, K.; Matsubara, R.; Kobayashi, S.; Hanada,
K.; Wakatsuki, S.; Kato, R. J. Mol. Biol. 2010, 396, 245–251.
(5) Raghavan, S.; Rajender, A. Tetrahedron 2004, 60, 5059–5067.
(6) Ueno, M.; Kitagawa, H.; Ishitani, H.; Yasuda, S.; Hanada, K.;
Kobayashi, S. Tetrahedron Lett. 2001, 42, 7863–7865.
(7) (a) Kobayashi, S.; Matsubara, R.; Nakamura, Y.; Kitagawa, H.;
Sugiura, M. J. Am. Chem. Soc. 2003, 125, 2507–2515. (b) Manabe, K.;
Kobayashi, S. Chem.;Eur. J. 2002, 8, 4095–4101. (c) Hamada, T.;
Manabe, K.; Kobayashi, S. Chem.;Eur. J. 2006, 12, 1205–1215.
(8) Nakamura, Y.; Matsubara, R.; Kitagawa, H.; Kobayashi, S.;
Kumagai, K.; Yasuda, S.; Hanada, K. J. Med. Chem. 2003, 46, 3688–
3695.
(9) (a) Barfoot, C. W.; Harvey, J. E.; Kenworthy, M. N.; Kilburn,
J. P.; Ahmed, M.; Taylor, R. J. K. Tetrahedron 2005, 61, 3403–3417. (b)
Jorda-Gregori, J. M.; Gonzalez, R.; Cava-Montesinos, P.; Sepulveda-
Arques, J.; Galeazzi, R.; Orena, M. Tetrahedron: Asymmetry 2000, 11,
3769–3777. (c) Gonzalez-Rosende, M.; Jordagregori, J.; Sepulveda-arques,
J.; Orena, M. Tetrahedron: Asymmetry 2004, 15, 419–422. (d) Yan, G.; Wu,
Y.; Lin, W.; Zhang, X. Tetrahedron: Asymmetry 2007, 18, 2643–2648.
(10) (a) Partridge, K. M.; Guzei, I. A.; Yoon, T. P. Angew. Chem., Int.
Ed. 2010, 122, 942–946. (b) Morita, N.; Fukui, K.; Irikuchi, J.; Sato, H.;
Takano, Y.; Okamoto, I.; Ishibashi, H.; Tamura, O. J. Org. Chem. 2008,
73, 7164–7174.
ꢀ
ꢀ
(11) (a) Berkes, D.; Kolarovic, A.; Manduch, R.; Baran, P.;
ꢀ
Povazanec, F. Tetrahedron: Asymmetry 2005, 16, 1927–1934. (b)
ꢀ
ꢀ
ꢀ
Jakubec, P.; Berkes, D.; Kolarovic, A.; Povazanec, F. Synthesis
ꢀ
ꢀ
ꢀ
ꢁ
ꢀ
ꢁ
ꢁ
2006, 4032–4040. (c) Berkes, D.; Korenova, A.; Safar, P.; Horvathova,
ꢁ
ꢁ
ꢀ
H.; Pronayova, N. Cent. Eur. J. Chem. 2007, 5, 688–705. (d) Berkes,
ꢁ
ꢀ
D.; Jakubec, P.; Winklerova, D.; Povazanec, F.; Daıch, A. Org.
ꢀ
¨
ꢁꢀ
ꢀ
Biomol. Chem. 2007, 5, 121–124. (e) Jakubec, P.; Petras, P.; Duris,
ꢀ
A.; Berkes, D. Tetrahedron: Asymmetry 2010, 21, 69–74.
(12) Berkes, D.; Kolarovic, A.; Povazanec, F. Tetrahedron Lett. 2000,
41, 5257–5260.
ꢀ
ꢀ
ꢀ
Org. Lett., Vol. 13, No. 7, 2011
1643